kxk016

Karen E. Knudsen, PhD

Contact Dr. Knudsen

Sidney Kimmel Cancer Center
233 South 10th Street
BLSB 1050
Philadelphia, PA 19107

(215) 503-5692

Most Recent Peer-reviewed Publications

  1. Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle
  2. Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: Results from NCI 9012
  3. Therapeutic challenge with a CDK 4/6 inhibitor induces an RB-dependent SMAC-mediated apoptotic response in non–small cell lung cancer
  4. Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017
  5. Differential impact of RB status on E2F1 reprogramming in human cancer
  6. Response and resistance to paradox-breaking BRAF inhibitor in melanomas in vivo and Ex vivo
  7. Detection of activating estrogen receptor gene (ESR1) mutations in single circulating tumor cells
  8. Posttranscriptional regulation of PARG mRNA by HuR facilitates DNA repair and resistance to PARP inhibitors
  9. Analysis of circulating cell-free DnA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors
  10. Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer
  11. PARP Inhibitors in Prostate Cancer
  12. Sigma1 targeting to suppress aberrant androgen receptor signaling in prostate cancer
  13. Not So Fast: Cultivating miRs as Kinks in the Chain of the Cell Cycle
  14. Cell cycle-coupled expansion of AR activity promotes cancer progression
  15. RB loss promotes prostate cancer metastasis
  16. Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report
  17. There and back again: The middle earth of DNA repair
  18. Linking DNA Damage and Hormone Signaling Pathways in Cancer
  19. Patient-level DNA damage and repair pathway profiles and prognosis after prostatectomy for high-risk prostate cancer
  20. Downregulation of critical oncogenes by the selective SK2 Inhibitor ABC294640 hinders prostate cancer progression